|
|
|
|
| 專題 |
最後回覆 |
暱稱 |
內容 |
| 信達生物製藥 |
2020-07-15T11:12 |
財經茄呢啡 |
信達生物（1801）旗下PD-1藥物信迪利單抗為公司去年帶來10億人民幣巨額收入，市場憧憬相關藥物的銷售潛力。 |
|
|
|
|
We've noticed you're using an ad blocker
We spend millions of dollars each year so you can access, for FREE, the highest quality real-time quotes and charts. This is made possible only thanks to the advertising on our site.
To continue using 88iv.com, please allow this domain on your ad blocker.
We are thanksful for your decisive action.
This notice will be shown again every hour.
Close This Window